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INTRODUCTION: The role of leptin has been more clear
in the endocrinology area after the discovery of its
secretion from the adipose tissue. The aim of the
study is to investigate the leptin levels in obese
women in whom type 2 diabetes mellitus were
present or absent.
Materials and methods: Thirty-five obese women
with type 2 diabetes mellitus (group 1) and 34 obese
women without type 2 diabetes mellitus (group 2)
were enrolled in the study. In both groups the body
mass index (BMI), waist circumference, and waist-to-
hip ratio were measured. Leptin, HbA1c, creatinine
and the lipid profile were assessed.
Results: Leptin was found to be statistically signifi-
cantly lower in group 1 than in group 2 (40.229 /17.77
ng/ml versus 50.129 /15.51 ng/ml, respectively; p /
0.019). It was well correlated with BMI in group 1
(r /0.60, p /0.0001). In group 1 also, correlation of
leptin was moderate with creatinine and high-density
lipoprotein-cholesterol (r /0.36, p /0.037 versus
r /0.37, p /0.027, respectively), whereas triglycer-
ide had a negative correlation (r / /0.34, p /0.046).
In group 2, the only significant correlation with
leptin was BMI (r /0.41, p /0.02). Leptin was also
significantly lower in 17 subjects with poorly con-
trolled diabetes mellitus than in 18 well-controlled
diabetics (33.549 /15.82 ng/ml versus 44.619 /17.54
ng/ml, respectively; p /0.038).
Conclusion: Since leptin is lower in obese women
with diabetes than without diabetes and additionally
it is even lower in the poorly controlled diabetes
subgroup, we think that further studies are required
to make clear the issue for lower leptin levels,
whether it is a reason or an outcome.
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Introduction
Obesity that is associated with a chronic low-grade
inflammation state is an increasing worldwide health
problem.
1 In the pathogenesis, a genetic tendency,
disturbances of thermogenesis in the central nervous
system, and impairment of the signals from the
adipose tissue on the way to the brain are believed
to play a major role.
2,3 It is gaining more and more
importance since the mechanism leading to type 2
diabetes mellitus*/another epidemic metabolic
issue*/in both adolescents and adults is more
comprehensible after recent studies.
4
Leptin together with other molecules that are
secreted from the adipose tissue does affect the
insulin sensitivity, and it is accepted to play a role
in the pathogenesis of obesity-related disorders
5,6 via
stimulating vascular inflammation and oxidative
stress that may contribute to pathogenesis of athero-
sclerosis and other cardiovascular complications of
obesity.
7,8 It has also a link with nutritional status and
energy balance*/which are both important in the
physiopathology of diabetes*/and proinflammatory
T-helper 1 immune responses.
9 Strong positive cor-
relations found between interleukin-6, tumor necro-
sis factor alpha, leptin and serum C-reactive protein
suggest that cytokines secreted by adipose tissue in
obese subjects may play a role in increased inflam-
matory proteins secretion by the liver.
8,10 Its possible
role in liver disease as a fat deposition, in inflamma-
tion and fibrosis,
11 in overexpression in intestinal
inflammation,
12 by activating nuclear factor-kap-
paB,
13 and inappropriate increase independent of
body mass index (BMI) in acute ulcerative colitis
14
have been studied by many investigators.
Approximately 80% of the subjects with type 2
diabetes mellitus are obese. As long as the obesity
continues, the risk of development of type 2 diabetes
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15 It has been found that
subjects who have obesity for over 10 years have a
two times greater risk for diabetes than the subjects
who have obesity for less than 5 years.
15 In gesta-
tional diabetes mellitus, major changes were in
the expression profile of placental genes with a
prominent increase in markers and mediators of
inflammation.
16 Regarding this, upregulation of
interleukins, leptin and tumor necrosis factor alpha
receptors and their downstream molecular adaptors
indicate an activation of pathway recruiting stress
activated protein-kinases leading to reorganization of
placenta.
16
In an eastern Mediterranean area of Turkey where
the prevalence of type 2 diabetes is quite high
17 we
aimed to investigate leptin levels in obese female
subjects with type 2 diabetes mellitus and in a small
group with poor glycemic control.
Research design and methods
Subjects
In the study, subjects were collected consecutively
from the Outpatient Department of Internal Medi-
cine, Kahramanmaras Sutcu Imam University, Faculty
of Medicine. All the participants were obese women
with normal creatinine levels. Subjects with type 2
diabetes mellitus (group 1) numbered 35 and those
without diabetes (group 2) numbered 34. All diabetic
subjects met the American Diabetes Association
criteria for type 2 diabetes mellitus.
18 Patients having
HbA1c greater than 8.5% were accepted as poorly
controlled diabetes. Seventeen subjects were poorly
controlled diabetics.
The height (m), weight (kg) and BMI (kg/m
2) were
recorded. All subjects had a BMI equal to or greater
than 30 for participating in the study as the obese
subject. The waist (waist circumference was mea-
sured with a soft tape on standing subjects, mid-way
between the lowest rib and iliac crest), hip (hip
circumference was measured over the widest part of
the gluteal region) and therefore waist-to hip-ratio
were all measured by the same investigator so as to
minimalize interobserver variability during each
measurement.
For group 2, in order to exclude new onset
diabetes, subjects who were known not to have
diabetes by taking history were asked to drink 75 g of
glucose for the oral glucose tolerance test.
Local Research Ethics Commitee approval was
taken for the study before it commenced. Patients
were also asked to sign a consent form.
Physical examinations, BMI, waist and hip mea-
surements and routine laboratory measurements
except leptin were performed in Kahramanmaras
Sutcu Imam University Faculty of Medicine.
Samples and measurements
Before collecting venous blood samples using stan-
dard venipuncture into plain tubes, subjects were
asked to have a fasting period of 12 h. For the
standardization blood was drawn in a sitting position
from the antecubital vein. Leptin, total cholesterol,
low-density lipoprotein-cholesterol, high-density li-
poprotein (HDL)-cholesterol, triglyceride and creati-
nine were kept in plain tubes, whereas for HbA1c
special tubes containing K3EDTA were provided so
as not to give rise to coagulation. All measurements
were performed daily except for leptin. Leptin
levels were measured at the Laboratories of Depart-
ment of Biochemistry, Gaziantep University, Faculty
of Medicine.
Lipids and creatinine levels were measured by
biochemical autoanalyzer via enzymatic-calorimetric
method (Roche-Hitachi Modular Analytics, Tokyo,
Japan). Low-density lipoprotein cholesterol was cal-
culated via the Friedewald formula.
19 For HbA1ca n
autoanalyzer (DCA 2000; Bayer, USA) was used via
the method of inhibition of latex agglutination.
Sera that were separated immediately after centri-
fugation with 3000  /g for 10 min were stored at
  /208C until the assays for leptin were performed
and the last subject fulfilling the inclusion criteria was
admitted. Serum leptin levels were measured using
the enzyme-linked immunosorbent assay kit (Diag-
nostic Systems Laboratories, Inc., Webster, TX, USA).
Analytical sensitivity of the leptin assay was 0.05
ng/ml. The intra-assay coefficient of variation was
3.7% and the interassay coefficient of variation was
4.43%.
Statistical analysis
Results are presented as the mean9 /standard devia-
tion. Data collected were analyzed by SPSS for
Windows package (version 9.05; SPSS, Chicago, IL,
USA). Leptin levels of group 1 and group 2 were
compared via an independent t-test. Correlation of
leptin with the other parameters were evaluated via
Pearson correlation analyses. For the comparison of
the leptin levels between subgroups who had well
and poorly controlled diabetes mellitus the Mann /
Whitney U-test was used since the distributions of the
data were not normal. For all statistical assessments a
value of pB /0.05 was accepted to be statistically
significant.
Results
Baseline characteristics and biochemical parameters
of subjects in the diabetic and control groups are
summarized in Table 1. The mean age of group 1
was 49.979 /6.45 years and that of group 2 was
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and group 2 was 36.849 /3.60 kg/m
2 and 37.589 /2.95
kg/m
2, respectively (p  /0.05).
When we compared group 1 and group 2 regard-
ing weight, height, waist circumference, hip circum-
ference, waist-to-hip ratio, creatinine and lipid
profile, no difference was observed (Table 1).
However, the leptin level in group 1 (40.229 /17.77
ng/ml) was lower than in group 2 (50.129 /15.51
ng/ml) (p  /0.019) (Fig. 1). Of the thirty-five diabetic
subjects the mean HbA1c was 8.089 /2.12%. The
leptin level of 17 subjects who had poorly controlled
diabetes was 33.549 /15.82 ng/ml, whereas 18 well-
controlled diabetic subjects had a leptin level of
44.619 /17.54 ng/ml (p  /0.038) (Fig. 2).
Leptin was well correlated with BMI in group
1( r  /0.60, p  /0.0001). In group 1, also, while the
correlation of leptin was moderate with creatin-
ine and HDL-cholesterol (r  /0.36, p  /0.037 versus
r  /0.37, p  /0.027, respectively), triglyceride had a
negative correlation (r  /  /0.34, p  /0.046). In group
2, the only correlation with leptin was BMI (r  /0.41,
p  /0.02) (Table 2).
Discussion
After the discovery of leptin secretion from the
adipose tissue, its role has been more clear in the
endocrinology area. Even though leptin limits food
ingestion and increases energy expenditure, it has
been found high in obesity. This can be explained by
the statement that ‘‘obesity may be the consequence
of leptin resistance’’.
20 Decreased levels of leptin
concentrations during food deprivation leading to
impaired immune function gave rise to spending
more time to understand role of this molecule in
chronic inflammation and autoimmunity together
with therapeutic implications of its modulators.
21
Serum leptin levels are found higher in women
than in men,
20,22 25 and this is probably owing to
adipose tissue in women being higher than in the
opposite sex, the existence of negative correlation
between leptin and testosterone levels,
22,26 and the
stimulation of mRNA production by 17b-estradiol,
which is one of the female sexuality hormones.
27 All
the subjects enrolled in our study were female obese
subjects and we found no correlation between the
Table 1. Baseline characteristics and biochemical parameters of subjects with diabetes and the control group
Diabetic patients Control group p
Age (years) 49.979 /6.45 48.779 /4.08 Not significant
Weight (kg) 88.749 /8.72 89.439 /11.31 Not significant
Height (m) 155.259 /5.54 154.869 /5.7 Not significant
Body mass index (kg/m
2) 36.849 /3.60 37.589 /2.95 Not significant
Waist (cm) 107.089 /10.26 101.149 /10.65 Not significant
Hip (cm) 121.509 /12.11 115.859 /10.15 Not significant
Waist/hip (ratio) 0.889 /0.11 0.879 /0.08 Not significant
Leptin (ng/ml) 40.229 /17.77 50.129 /15.51 0.019
Creatinine (mg/dl) 0.789 /0.27 0.799 /0.09 Not significant
Total cholesterol (mg/dl) 208.179 /40.57 208.409 /48.65 Not significant
Low-density lipoprotein cholesterol (mg/dl) 125.559 /33.83 126.849 /43.88 Not significant
High-density lipoprotein cholesterol (mg/dl) 44.429 /10.21 50.869 /16.74 Not significant
Triglyceride (mg/dl) 208.689 /131.31 140.339 /74.21 Not significant
HbA1c (%) 8.089 /2.12 5.269 /0.48 0.001
34 35 N =
Control Diabetes
L
e
p
t
i
n
 
(
n
g
/
m
l
)
100
80
60
40
20
0
FIG. 1. Leptin levels in diabetes and control groups
(p  /0.019).
15 18 N =
Control
poorly controlled well controlled
L
e
p
t
i
n
100
80
60
40
20
0
34
FIG. 2. Leptin levels in subjects who have well and poorly
controlled diabetes mellitus (p  /0.038).
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demonstrated that leptin had a major correlation
with BMI.
20,22 24,28 33 In our study, also, leptin had
a correlation with BMI both for subjects with diabetes
and subjects who did not have diabetes. The BMI
seems to be applied easily at outpatient departments;
however, obesity itself cannot be defined simply by
this method only. Therefore, waist and hip circum-
ferences and the waist-to-hip ratio have all been
performed. As a result, we found no relationship with
leptin and waist or waist-to-hip ratio measurements
in diabetic and non-diabetic groups.
Leptin correlated positively with HDL-cholesterol
and negatively with triglycerides in the diabetic
group, as in the study where serum leptin concentra-
tions were investigated in a group of patients with
moderate and severe obesity.
24 The same correlations
were found to be independent of age and gender in a
Caucasion population.
30
Creatinine was found to have a correlation with
leptin in our diabetic group. This was matching with
the findings of another investigation, but none of the
participants had diabetes in that study.
34 Leptin is
known to accumulate in a uremic state; however,
leptin levels and renal creatinine clearence showed
no significant correlation in peritoneal dialysis pa-
tients.
35
Leptin has the ability of regulation of insulin
secretion from the pancreatic islet cells.
36,37 After
leptin was given to mice who had leptin deficiency, it
has been demonstrated that there had been a
decrease in hyperglycemia and hyperinsulinemia,
inhibition in hepatic gluconeogenesis and insulin
secretion via direct effects on beta cells.
29,38,39
Some investigators have found that in more obese
patients with type 2 diabetes mellitus, the leptin
levels were less in patients with not well controlled
diabetes than in well-controlled diabetic subjects.
40
This was related to the insulin deficiency. In our
study also, leptin levels were significantly lower in
patients who have HbA1c above 8.5%. It has been
found that untreated diabetes gave rise to a reduction
in leptin levels owing to an ineffective release of
insulin by the monodrug therapy.
41 An absence of
leptin receptor expression in human diabetic foot
ulcer, which is the consequence of poor glycemic
control for many years, was well documented while
investigating the role of leptin for the inflammatory
response in diabetes-impaired skin repair.
42 This may
show that leptin itself might function as a regulatory
link between endocrine and immune system in the
context of skin repair.
42 However, contrarily to these
findings, no significant relation between leptin levels
and the degree of the severity of diabetes was
observed in another study.
23
Abdominal fat tissue that can be detected by
densitometry, hydrometry, dual-energy X-ray absorb-
tiometry, a chemical multicompartment model, bioe-
lectrical impedance, computerized tomography and
magnetic resonance imaging is also well correlated
with leptin levels.
31 Leptin’s relationship with total
body fat and insulin resistance was independent of
age and gender.
24,25,43 In our study we did not
investigate the abdominal fat tissue percentage in
the participants with the aforementioned instruments
and imaging techniques.
We speculate that as a consequence of insulin
deficiency and the different distribution of fat tissue
throughout the body, we have found low leptin
levels in diabetic subjects and even lower levels in
subjects who have poorly controlled diabetes.
Further large-scale studies*/which should investi-
gate the physiopathologic mechanisms*/are re-
quired to make clear the issue for lower leptin
levels, whether it is a reason or an outcome.
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